Skip to main content
SpringerLink
Log in

Cardiotoxicity in Long-Term Survivors

  • Chapter
  • First Online:
Manual of Cardio-oncology

  • 667 Accesses

Abstract

Survivorship represents a new season of cancer with an increasing number of patients [1]. In Italy, there are 2.8 million patients diagnosed with cancer, twice as many as 15 years ago as a result of improved screening programs, therapeutic advances, and an aging society.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. De Angelis R, Sant M, Coleman MP, on behalf of the eurocare-5 Working Group, et al. Cancer survival in Europe 1999–2007 by country and age: results of eurocare-5—a population-based study. Lancet Oncol. 2014;15:23–34.

    Article  PubMed  Google Scholar 

  2. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24:5117–24.

    Article  PubMed  Google Scholar 

  3. Surbone A, Tralongo P. Categorization of cancer survivors: why we need it. J Clin Oncol. 2016 Jul 25. pii: JCO683870. [Epub ahead of print]

    Google Scholar 

  4. Leigh S. Cancer survivorship: today and tomorrow, 2007. Chapter 2, Ed Ganz P, Springer, New York, NY, pp 8–13

    Google Scholar 

  5. Institute of Medicine and the National Research Council. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2006.

    Google Scholar 

  6. Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006;24(32):5101–4.

    Article  PubMed  Google Scholar 

  7. Wu HS, Harden JK. Symptom burden and quality of life in survivorship: a review of the literature. Cancer Nurs. 2015;38(1):E29–54.

    Article  PubMed  Google Scholar 

  8. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.

    Article  CAS  PubMed  Google Scholar 

  9. Ky B, Vejpongsa P, Yeh ETH, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res. 2013;113(6):754–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987;19(8):817–28.

    Article  CAS  PubMed  Google Scholar 

  12. Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol. 2003;63(4):849–61.

    Article  CAS  PubMed  Google Scholar 

  13. Yeh E, Tong A, Lenihan D, et al. Cardiovascular complcations of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–31.

    Article  PubMed  Google Scholar 

  14. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Untern Med. 1996;125(1):47–58.

    Article  CAS  Google Scholar 

  15. Yeh E, Bickford C. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.

    Article  CAS  PubMed  Google Scholar 

  16. Perik PJ, de Vries EG, Gietema JA, van der Graaf WT, Smilde TD, Sleijfer DT, van Veldhuisen DJ. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail. 2007;9(2):173–7. Epub 2006 Jul 24.

    Article  CAS  PubMed  Google Scholar 

  17. Chien KR. Herceptin and the heart – a molecular modifier of cardiacfailure. N Engl J Med. 2006;354(8):789–90.

    Article  CAS  PubMed  Google Scholar 

  18. Ewer M, Lippman S. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2.

    Article  CAS  PubMed  Google Scholar 

  19. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47:887–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Force T, Krause DS, van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–44.

    Article  CAS  PubMed  Google Scholar 

  21. Cheng H, Force T. Molecular mechanisms of cardiovascula r toxicity of targeted cancer therapeutics. Circ Res. 2010;106:21–34.

    Article  CAS  PubMed  Google Scholar 

  22. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5):710–5.

    Article  CAS  PubMed  Google Scholar 

  24. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251(3):228–34.

    Article  CAS  PubMed  Google Scholar 

  25. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–25.

    Article  CAS  PubMed  Google Scholar 

  26. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.

    Article  CAS  PubMed  Google Scholar 

  27. Mavinkurve-Groothuis AMC, Marcus KA, Pourier M, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. 2013;14(6):562–9.

    Article  PubMed  Google Scholar 

  28. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5):710–5.

    Article  CAS  PubMed  Google Scholar 

  29. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol. 1992;19(5):529–42.

    CAS  PubMed  Google Scholar 

  30. von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.

    Article  Google Scholar 

  31. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332(26):1738–43.

    Article  CAS  PubMed  Google Scholar 

  32. De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 2010;106(1):35–46.

    Article  PubMed  CAS  Google Scholar 

  33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):182–91.

    Article  Google Scholar 

  34. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  CAS  PubMed  Google Scholar 

  35. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol. 2010;28(25):3901–4.

    Article  CAS  PubMed  Google Scholar 

  36. Ewer MS, Vooletich MT, Durand J-B, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–6.

    Article  CAS  PubMed  Google Scholar 

  37. Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res. 2008;14:2710–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.

    Article  CAS  PubMed  Google Scholar 

  39. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.

    Article  CAS  PubMed  Google Scholar 

  40. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as fi rst-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544–52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as fi rst-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538–46.

    Article  CAS  PubMed  Google Scholar 

  42. Steingart RM, Bakris GL, Chen HX et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012; 163(2): 156–63

    Google Scholar 

  43. Tocchetti CG, Gallucci G, Coppola C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15(5):482–9.

    Article  CAS  PubMed  Google Scholar 

  44. Force T, Krause DS, van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–44.

    Article  CAS  PubMed  Google Scholar 

  45. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMOclinical practice guidelines. Ann Oncol. 2012;23 Suppl 7:vii155–66.

    Article  PubMed  Google Scholar 

  46. Marone G, Granata F. Angiogenesis, lymphangiogenesis and clinical implications. Preface. Chem Immunol Allergy. 2014;99:11–2.

    Google Scholar 

  47. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12.

    Article  PubMed  Google Scholar 

  48. Gressett SM, Shah SR. Intricacies of bevacizumabinduced toxicities and their management. Ann Pharmacother. 2009;43(3):490–501.

    Article  CAS  PubMed  Google Scholar 

  49. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1–10.

    Article  PubMed  Google Scholar 

  50. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444–8.

    Article  CAS  PubMed  Google Scholar 

  51. Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest. 2007;117(11):3176–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  CAS  PubMed  Google Scholar 

  53. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  CAS  PubMed  Google Scholar 

  54. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.

    Article  CAS  PubMed  Google Scholar 

  55. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792–9.

    Article  CAS  PubMed  Google Scholar 

  56. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29:632–8.

    Article  CAS  PubMed  Google Scholar 

  57. Gressett SM, Shah SR. Intricacies of bevacizumab induced toxicities and their management. Ann Pharmacother. 2009;43(3):490–501.

    Article  CAS  PubMed  Google Scholar 

  58. Chintalgattu V, Ai D, Langley RR, et al. Cardiomyocyte PDGFR-\( \beta \) signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Investig. 2010;120(2):472–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010;106(1):21–34.

    Article  CAS  PubMed  Google Scholar 

  60. Anisimov A, Alitalo A, Korpisalo P, et al. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 2009;104(11):1302–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation. 2003;10(2):113–26.

    Article  PubMed  Google Scholar 

  62. Kerkela R, Woulfe KC, Durand J-B, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMPactivated protein kinase. Clin Transl Sci. 2009;2(1):15–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535–42.

    Article  PubMed  Google Scholar 

  64. Mourad J, Levy BI. Mechanisms of antiangiogenicinduced arterial hypertension. Curr Hypertens Rep. 2011;13(4):289–93.

    Article  CAS  PubMed  Google Scholar 

  65. Goodwin R, Ding K, Seymour L, et al. Treatment-emergent hypertension and outcomes in patients with advanced nonsmall-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol. 2010;21(11):2220–6.

    Article  CAS  PubMed  Google Scholar 

  66. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20(2):227–30.

    Article  CAS  PubMed  Google Scholar 

  67. Molinaro M, Ameri P, Marone G, et al. Recent advances on pathophysiology diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic. Drugs Biomed Res Int. 2015;2015:138148.

    PubMed  Google Scholar 

  68. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.

    Article  CAS  PubMed  Google Scholar 

  69. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304:172–9.

    Article  CAS  PubMed  Google Scholar 

  70. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725–32.

    Article  CAS  PubMed  Google Scholar 

  71. Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis. 2010;53:88–93.

    Article  PubMed  Google Scholar 

  72. van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010;170:1247–55.

    PubMed  Google Scholar 

  73. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.

    Article  CAS  PubMed  Google Scholar 

  74. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743–9.

    Article  PubMed  Google Scholar 

  75. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.

    Article  CAS  PubMed  Google Scholar 

  76. Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011;108:619–28.

    Article  CAS  PubMed  Google Scholar 

  77. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Available at: http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_ 5x7.pdf. Accessed May 28, 2009.

    Google Scholar 

  78. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–54.

    Article  CAS  PubMed  Google Scholar 

  79. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys. 2007;67:10–8.

    Article  CAS  PubMed  Google Scholar 

  80. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008;26:1201–3.

    Article  PubMed  Google Scholar 

  81. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2009;14:14–24.

    Article  CAS  Google Scholar 

  82. Martin M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist. 2009;14:1–11.

    Article  CAS  PubMed  Google Scholar 

  83. Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26:3777–84.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53:105–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991–8.

    Article  CAS  PubMed  Google Scholar 

  86. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–15.

    Article  CAS  PubMed  Google Scholar 

  87. Andersson A, Naslund U, Tavelin B, et al. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors—retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124:1914–7.

    Article  CAS  PubMed  Google Scholar 

  88. Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 2012;18:113–9.

    Article  CAS  PubMed  Google Scholar 

  89. Du XL, Xia R, Liu CC, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115:5296–308.

    Article  PubMed  Google Scholar 

  90. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.

    Article  CAS  PubMed  Google Scholar 

  91. Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104:357–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365–75.

    Article  PubMed  Google Scholar 

  93. Telli ML, Witteles RM. Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw. 2011;9:243–9.

    Article  PubMed  Google Scholar 

  94. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med. 2008;356:125–34.

    Article  Google Scholar 

  95. Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol. 2011;29:3450–6.

    Article  CAS  PubMed  Google Scholar 

  96. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.

    Article  CAS  PubMed  Google Scholar 

  97. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.

    Article  PubMed  CAS  Google Scholar 

  98. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991–8.

    Article  CAS  PubMed  Google Scholar 

  99. Geiger S, Lange V, Suhl P, et al. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs. 2010;21:578–90.

    Article  CAS  PubMed  Google Scholar 

  100. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1–10.

    Article  PubMed  Google Scholar 

  101. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation [serial online]. J Am Coll Cardiol. 2009;53:e1–e90.

    Article  PubMed  Google Scholar 

  102. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 suppl 7:vii155–66.

    Article  PubMed  Google Scholar 

  103. Martin M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist. 2009;14:1–11.

    Article  CAS  PubMed  Google Scholar 

  104. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100:684–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008;26:1201–3.

    Article  PubMed  Google Scholar 

  106. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910–6.

    Article  CAS  PubMed  Google Scholar 

  107. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391–9.

    Article  CAS  PubMed  Google Scholar 

  108. Jenkins C, Leano R, Chan J, et al. Reconstructed versus real-time 3-dimensional echocardiography: comparison with magnetic resonance imaging. J Am Soc Echocardiogr. 2008;20:862–8.

    Article  Google Scholar 

  109. Cardinale D, Sandri MT. Role of biomarkers in chemotherapyinduced cardiotoxicity. Prog Cardiovasc Dis. 2010;53:121–129. Lenihan D MM, Baysinger KB, et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers [abstract]. J Card Fail. 2007;S151. Abstract 265.

    Google Scholar 

  110. Landier W, Bhatia S, Eshelman DA, et al. Development of riskbased guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;22:4979–90.

    Article  PubMed  Google Scholar 

  111. Skinner R, Wallace WH, Levitt GA. Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol. 2006;7:489–98.

    Article  PubMed  Google Scholar 

  112. Lenihan DJ. Statins in preparation for chemotherapy: “do these medications help your fitness for battle?”. J Am Coll Cardiol. 2012;60:2391–2.

    Article  CAS  PubMed  Google Scholar 

  113. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820–8.

    Article  CAS  PubMed  Google Scholar 

  114. Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56:1644–50.

    Article  PubMed  Google Scholar 

  115. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–20.

    Article  CAS  PubMed  Google Scholar 

  116. Cardinale D. Chapter 90: cardiovascular complication of cancer therapeutic agents. In: Bonow RO, Zipes DP, Libby P, editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. 9th ed. Philadelphia, PA: Saunders Elsevier; 2012.

    Google Scholar 

  117. Shukla A, Yusuf SW, Daher I, Lenihan D, Durand JB. High mortality rates are associated with withdrawal of beta blockers and ACE inhibitors in chemotherapy-induced heart failure [abstract]. Circulation. 2008;118:S797. Abstract 2942.

    Article  Google Scholar 

  118. Ewer M, Lippman S. Type II Chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2.

    Article  CAS  PubMed  Google Scholar 

  119. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–15.

    Article  CAS  PubMed  Google Scholar 

  120. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365–75.

    Article  PubMed  Google Scholar 

  121. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer—a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2010;19:170–81.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419–24.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104:357–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991;68(6):1221–9.

    Article  CAS  PubMed  Google Scholar 

  125. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol. 2004;5(11):654.

    Article  CAS  PubMed  Google Scholar 

  127. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. Clin Oncol. 2009;127(1):127–45.

    Article  CAS  Google Scholar 

  128. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol. 2004;93(9A):3B–6B.

    Article  CAS  PubMed  Google Scholar 

  129. Bryant J, Picot J, Levitt G, et al. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review . Health Technol Assess. 2007; 11(27): iii, ix–x, 1–84.

    Google Scholar 

  130. Andersson A, Naslund U, Tavelin B, Enblad G, Gustavsson A, Malmer B. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors – retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124(8):1914–7.

    Article  CAS  PubMed  Google Scholar 

  131. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Pediatrics. 1992;89:942–9.

    CAS  PubMed  Google Scholar 

  132. Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461–70.

    Article  CAS  PubMed  Google Scholar 

  133. Kapusta L, Thijssen JM, Groot-Loonen J, et al. Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines. Ultrasound Med Biol. 2001;27:1605–14.

    Article  CAS  PubMed  Google Scholar 

  134. Kapusta L, Thijssen JM, Groot-Loonen J, et al. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol. 2000;26:1099–108.

    Article  CAS  PubMed  Google Scholar 

  135. www.cardioncology.com [accessed 22 January 2013].

Download references

Author information

Authors and Affiliations

  1. Interdisciplinary Unit for Survivors and Chronic Cancer Patients “Lia Buccheri e Nino Tralongo”, UO Medical Oncology, RAO, Hospital Umberto I, Siracusa, Italy

    Paolo Tralongo, Sebastiano Bordonaro & Antonino Carmelo Tralongo

  2. Department of Medical Oncology, National Cancer Institute Aviano (PN), Pordenone, Italy

    Massimiliano Berretta

Authors
  1. Paolo Tralongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastiano Bordonaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonino Carmelo Tralongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimiliano Berretta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Tralongo .

Editor information

Editors and Affiliations

  1. Cardiology Unit, IRCCS CRO-National Cancer Institute, Aviano (PN), Italy

    Chiara Lestuzzi

  2. Cardiology Unit, National Cancer Institute “Giovanni Paolo II”, Bari, Italy

    Stefano Oliva

  3. Medical Oncology Unit, Ospedale San Vincenzo, Taormina, Italy

    Francesco Ferraù

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Tralongo, P., Bordonaro, S., Tralongo, A.C., Berretta, M. (2017). Cardiotoxicity in Long-Term Survivors. In: Lestuzzi, C., Oliva, S., Ferraù, F. (eds) Manual of Cardio-oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-40236-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40236-9_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40234-5

  • Online ISBN: 978-3-319-40236-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation